Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE).

Authors :: Kileel, Emma M
Malvestutto, Carlos D
Lo, Janet
Fitch, Kathleen V
Fichtenbaum, Carl J
Aberg, Judith A
Zanni, Markella V
Martinez, Esteban
Okeke, Nwora Lance
Kumar, Princy
Joao, Esau
Bares, Sara H
Berrner, Daniel
Smieja, Marek
Roa, Jhoanna C
McCallum, Sara
Douglas, Pamela S
Ribaudo, Heather J
Grinspoon, Steven K
Source :: Clinical Infectious Diseases; Jun2023, Vol. 76 Issue 11, p2010-2013, 4p
Publication Year :: 2023
Abstract: Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m<superscript>2</superscript>/year; 95% confidence interval [CI],.22 to.33 vs +0.17 kg/m<superscript>2</superscript>/year; 95% CI,.12 to.23; P =.01), but not those on an entry INSTI >2 years. [ABSTRACT FROM AUTHOR]

Subjects :: HIV infections
DISEASE clusters
HIV integrase inhibitors
CONFIDENCE intervals
ANTIRETROVIRAL agents
TREATMENT duration
WEIGHT gain
TREATMENT effectiveness
RESEARCH funding
DESCRIPTIVE statistics
BODY mass index
LONGITUDINAL method

Full Text Access

Tools